Rebecca Larson, MD

Dermatologist
Dermatology
Accepting new patients
Call for an appointment
or

    About me

    Academic Interests: Prevention of melanoma and nonmelanoma skin cancer; reconstructive dermatologic surgery; procedural dermatology education; patient safety

    Clinical Interests:  Melanoma and nonmelanoma skin cancer; Mohs Micrographic Surgery; transplant dermatology; medical dermatology; pursuit of the imperceptible surgical scar

    Gender

    Female

    Education & training

    Positions
    Associate Professor of Clinical Internal Medicine, Division of Dermatology
    Board Certifications
    Dermatology
    Medical School
    Loma Linda University School of Medicine, Loma Linda, CA - 2008
    Undergraduate Degree
    Concordia College, Moorehead, MN - 2004
    Residency
    SIU School of Medicine, Springfield, IL - Internal Medicine Internship; Dermatology Residency - 2012
    Fellowship
    University of Wisconsin School of Medicine and Public Health, Madison, WI - Dermatology Fellowship and Mohs Surgery Program - 2014

    Specialties

    Clinical locations

    Locations

    SIU Dermatology Clinic

    751 N. Rutledge St. Springfield, IL 62702
    Mon - Fri: 8:00 am-4:30 pm

    Hospital privileges

    • HSHS St. John's Hospital, Springfield, IL
    • Memorial Health, Springfield IL

    Research

    Research Interests
    Cutaneous Oncology, Mohs Micrographic and Dermatologic Surgery, General Dermatology, MOHS Micrographic Surgery.

    Clinical trials

    Trial
    Dermatology

    Corrona Psoriasis (PSO) Registry

    Active recruiting

    The objective of the Corrona Psoriasis Registry is to create a national database of patients with psoriasis. Data collected will be used to study the  disease and to evaluate the effectiveness and safety of medications approved for the treatment of psoriasis.

    Trial
    Dermatology

    A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA

    Active not recruiting

    The purpose of this study is to evaluate the long-term safety, tolerability, and effectiveness of PF-06651600(Ritlecitinib) in adult and adolescent (12 years and older) participants with Alopecia Areata.